{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T13:35:36Z","timestamp":1782135336404,"version":"3.54.5"},"reference-count":17,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T00:00:00Z","timestamp":1671667200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100014476","name":"Pfizer Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014476","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Cardiovascular disease (CVD) has become a leading cause of morbidity and mortality among people with HIV. Atorvastatin is known to reduce cardiovascular risk. We (1) compared atorvastatin concentrations between different boosted protease inhibitors (PIs) and with lipid outcomes and (2) compared pre\u2010atorvastatin 25\u2010OH vitamin D levels with atorvastatin concentrations and with lipid outcomes, in people with HIV with suppressed HIV\u20101 RNA and low\u2010density lipoprotein cholesterol (LDL\u2010C)\u2009&lt;130 mg\/dL.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A5275 was a randomized, double\u2010blind, placebo\u2010controlled crossover study of atorvastatin in virally suppressed people with HIV with fasting LDL\u2010C &lt;130\u2009mg\/dL. We analyzed results over the 20\u2009weeks of active atorvastatin treatment. Atorvastatin was initiated at 10\u00a0mg daily and increased to 20\u2009mg daily after 4\u2009weeks if there were no findings of toxicity. Atorvastatin trough concentrations were measured at week 20. Participants took combination antiretroviral therapy (ART) that included a boosted PI throughout.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall (<jats:italic>n<\/jats:italic>\u00a0=\u00a067), 70% of participants were male, and the median age was 51\u2009years. There was no apparent association between atorvastatin trough concentrations and pre\u2010atorvastatin vitamin D levels (<jats:italic>r<\/jats:italic>\u00a0=\u00a00.01, <jats:italic>p<\/jats:italic>\u00a0=\u00a00.9) or by boosted PI (<jats:italic>p<\/jats:italic>\u00a0=\u00a00.20). Median pre\u2010 to post\u2010atorvastatin change was \u221239.0\u00a0mg\/dL in fasting total cholesterol, \u221240.4\u00a0ng\/mL in lipoprotein\u2010associated phospholipase A2 (LP\u2010PLA2), and\u2009\u221213.8\u00a0U\/L in oxidized LDL, with all changes negatively correlated with atorvastatin trough concentrations (<jats:italic>r<\/jats:italic>\u00a0=\u00a0\u22120.19, \u22120.09, \u22120.21; <jats:italic>p<\/jats:italic>\u2009\u2265\u20090.096).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>No apparent associations between pre\u2010atorvastatin vitamin D levels and outcomes were observed (all <jats:italic>p<\/jats:italic>\u2009&gt;\u20090.70). In virologically suppressed people with HIV, higher atorvastatin concentrations were marginally associated with greater decreases in lipid outcomes.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hiv.13453","type":"journal-article","created":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T02:25:16Z","timestamp":1671762316000},"page":"749-753","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluating the effect of atorvastatin exposure and vitamin D levels on lipid outcomes in people with <scp>HIV<\/scp>\u20101 with suppressed <scp>HIV<\/scp>\u20101 <scp>RNA<\/scp> and <scp>LDL<\/scp> cholesterol &lt;130\u2009mg\/<scp>dL<\/scp>"],"prefix":"10.1111","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8696-8730","authenticated-orcid":false,"given":"Farah","family":"Rahman","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases Icahn School of Medicine at Mount Sinai  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irena","family":"Brates","sequence":"additional","affiliation":[{"name":"Center for Biostatistics and Research Harvard School of Public Health  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Aweeka","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy University of California  San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald J.","family":"Bosch","sequence":"additional","affiliation":[{"name":"Center for Biostatistics and Research Harvard School of Public Health  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Deitchman","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy University of California  San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Nixon","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Medicine Virginia Commonwealth University  Richmond Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith A.","family":"Aberg","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases Icahn School of Medicine at Mount Sinai  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,12,22]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-2190"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2013.3728"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcm.2019.01.001"},{"key":"e_1_2_12_5_1","unstructured":"NixonD AbergJ BoschR et al.Effects of atorvastatin on biomarkers of immune activation inflammation and lipids in virologically suppressed human immunodeficiency virus\u20101\u2010infected individuals with low\u2010density lipoprotein cholesterol."},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/nu13103603"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.8950"},{"key":"e_1_2_12_8_1","article-title":"Vitamin D levels and lipid response to atorvastatin, int","volume":"2010","author":"Perez\u2010Castrukkib JL","year":"2010","journal-title":"J Endocrinol"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.165"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2011.06.003"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2006.11.036"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph15080962"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200342130-00005"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/ejcn.2010.176"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/978\u20103\u2010319\u201056017\u20105_18"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra070553"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbiomolbio.2006.02.001"},{"key":"e_1_2_12_18_1","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents.Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. Available athttps:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-arv. Accessed 24 Jan 2022 [Table 7]"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.13453","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hiv.13453","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.13453","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T13:17:43Z","timestamp":1692537463000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.13453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,22]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1111\/hiv.13453"],"URL":"https:\/\/doi.org\/10.1111\/hiv.13453","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,22]]},"assertion":[{"value":"2022-07-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}